Boston Scientific Corp
NYSE:BSX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
105.4B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
187.8B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
130.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.4B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
169.4B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.2B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
33.1B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Boston Scientific Corp
Glance View
In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Boston Scientific Corp is 69%, which is below its 3-year median of 69.1%.
Over the last 3 years, Boston Scientific Corp’s Gross Margin has increased from 69% to 69%. During this period, it reached a low of 68.3% on Jun 30, 2025 and a high of 69.7% on Jun 30, 2023.